JP2002513748A - ゲル化性薬剤組成物 - Google Patents
ゲル化性薬剤組成物Info
- Publication number
- JP2002513748A JP2002513748A JP2000546752A JP2000546752A JP2002513748A JP 2002513748 A JP2002513748 A JP 2002513748A JP 2000546752 A JP2000546752 A JP 2000546752A JP 2000546752 A JP2000546752 A JP 2000546752A JP 2002513748 A JP2002513748 A JP 2002513748A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition according
- acid
- pharmaceutical composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 161
- 239000003814 drug Substances 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 title claims description 9
- 239000013543 active substance Substances 0.000 claims abstract description 37
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 19
- 239000000194 fatty acid Substances 0.000 claims abstract description 19
- 229930195729 fatty acid Natural products 0.000 claims abstract description 19
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 239000008346 aqueous phase Substances 0.000 claims abstract description 12
- 238000013270 controlled release Methods 0.000 claims abstract description 11
- 239000012530 fluid Substances 0.000 claims abstract description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 13
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 13
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 13
- 239000005642 Oleic acid Substances 0.000 claims description 13
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 13
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 13
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 239000007927 intramuscular injection Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 claims description 3
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 229960002446 octanoic acid Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000055006 Calcitonin Human genes 0.000 description 10
- 108060001064 Calcitonin Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 229960004015 calcitonin Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 241000208818 Helianthus Species 0.000 description 5
- 235000003222 Helianthus annuus Nutrition 0.000 description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 5
- 208000005888 Periodontal Pocket Diseases 0.000 description 5
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- -1 unsaturated fatty acid diacylglycerol Chemical class 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 101000607872 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 21 Proteins 0.000 description 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 102100039918 Ubiquitin carboxyl-terminal hydrolase 21 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- WDRFFJWBUDTUCA-UHFFFAOYSA-N chlorhexidine acetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229950011479 hyclate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 description 1
- 229950006240 hydrocortisone succinate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002476 metronidazole benzoate Drugs 0.000 description 1
- CUUCCLJJOWSASK-UHFFFAOYSA-N metronidazole benzoate Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOC(=O)C1=CC=CC=C1 CUUCCLJJOWSASK-UHFFFAOYSA-N 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940070805 p-chloro-m-cresol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical group OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000000822 sequential centrifugation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE09800329 | 1998-04-30 | ||
| BE9800329A BE1011899A6 (fr) | 1998-04-30 | 1998-04-30 | Compositions pharmaceutiques gelifiables utilisables. |
| PCT/EP1999/002551 WO1999056725A1 (fr) | 1998-04-30 | 1999-04-16 | Compositions pharmaceutiques gelifiables |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002513748A true JP2002513748A (ja) | 2002-05-14 |
| JP2002513748A5 JP2002513748A5 (https=) | 2005-08-18 |
Family
ID=3891230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000546752A Pending JP2002513748A (ja) | 1998-04-30 | 1999-04-16 | ゲル化性薬剤組成物 |
| JP2000546753A Withdrawn JP2002513749A (ja) | 1998-04-30 | 1999-04-16 | 歯根療法へのゲル化できる医薬組成物の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000546753A Withdrawn JP2002513749A (ja) | 1998-04-30 | 1999-04-16 | 歯根療法へのゲル化できる医薬組成物の使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6464987B1 (https=) |
| EP (2) | EP1073415B1 (https=) |
| JP (2) | JP2002513748A (https=) |
| KR (1) | KR100567975B1 (https=) |
| CN (1) | CN1183901C (https=) |
| AT (2) | ATE219659T1 (https=) |
| AU (2) | AU3708599A (https=) |
| BE (1) | BE1011899A6 (https=) |
| BG (1) | BG64723B1 (https=) |
| BR (1) | BR9910066A (https=) |
| CA (1) | CA2330500C (https=) |
| DE (2) | DE69901951T2 (https=) |
| DK (1) | DK1073415T3 (https=) |
| EA (1) | EA002530B1 (https=) |
| ES (2) | ES2249891T3 (https=) |
| HU (1) | HU226556B1 (https=) |
| ID (1) | ID26221A (https=) |
| IL (1) | IL139113A0 (https=) |
| IS (1) | IS2354B (https=) |
| NO (1) | NO20005431L (https=) |
| NZ (1) | NZ507707A (https=) |
| RS (1) | RS50025B (https=) |
| TR (1) | TR200003158T2 (https=) |
| WO (2) | WO1999056726A1 (https=) |
| ZA (1) | ZA200005915B (https=) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007510705A (ja) * | 2003-11-07 | 2007-04-26 | カムルス エービー | 脂質及びカチオン性ペプチドの組成物 |
| JP2008501676A (ja) * | 2004-06-04 | 2008-01-24 | カムルス エービー | 流体デポ製剤 |
| JP2008518916A (ja) * | 2004-10-28 | 2008-06-05 | アイデックス ラボラトリーズ，インコーポレイティド | 医薬活性化合物を制御して搬送するための組成物 |
| JP2008526932A (ja) * | 2005-01-14 | 2008-07-24 | カムルス エービー | 局所用生体付着性製剤 |
| JP2008526933A (ja) * | 2005-01-14 | 2008-07-24 | カムルス エービー | ソマトスタチン類似体製剤 |
| JP2008542437A (ja) * | 2005-06-06 | 2008-11-27 | カムルス エービー | Ｇｌｐ−１類似体製剤 |
| JP2012214494A (ja) * | 2005-01-14 | 2012-11-08 | Camurus Ab | 局所用生体付着性製剤 |
| JP2014527896A (ja) * | 2011-09-28 | 2014-10-23 | グローバス メディカル インコーポレイティッド | 生分解性パテ組成物およびインプラントデバイス、方法、ならびにこれらに関するキット |
| JP2015516412A (ja) * | 2012-05-10 | 2015-06-11 | ペインリフォーム リミテッド | 局所麻酔薬のデポー製剤及びその調製方法 |
| JP2018530561A (ja) * | 2015-10-08 | 2018-10-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 被包した薬剤の送達のための安定化させた集合ナノ構造体 |
| JP7092922B1 (ja) | 2021-06-11 | 2022-06-28 | キユーピー株式会社 | 製剤 |
| US11672864B2 (en) | 2010-09-24 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
Families Citing this family (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| ES2211151T3 (es) | 1998-08-19 | 2004-07-01 | Skyepharma Canada Inc. | Dispersiones acuosas inyectables de propofol. |
| US11026768B2 (en) | 1998-10-08 | 2021-06-08 | Align Technology, Inc. | Dental appliance reinforcement |
| DE10024413A1 (de) * | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
| DE10057769A1 (de) | 2000-11-22 | 2002-05-23 | Beiersdorf Ag | Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen |
| ES2561108T3 (es) * | 2001-10-19 | 2016-02-24 | Idexx Laboratories, Inc. | Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| FR2837099B1 (fr) * | 2002-03-12 | 2005-03-18 | Ethypharm Sa | Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives |
| BRPI0308360B8 (pt) * | 2002-03-12 | 2021-05-25 | Ethypharm Sa | composição termossensível sob forma liquida compreendendo substância organogelificante, utilização de uma composição e processo de preparação de uma composição |
| US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
| US8435942B2 (en) * | 2002-05-31 | 2013-05-07 | Transdermal Biotechnology, Inc. | Methods for formulating stabilized insulin compositions |
| US20050031650A1 (en) * | 2002-08-26 | 2005-02-10 | Ethypharm | Composition with gelling properties for the sustained delivery of bioactive substances |
| DE10255195A1 (de) * | 2002-11-27 | 2004-06-09 | Lipoid Gmbh | Micellare wasserlösliche Konzentrate |
| US20070232695A1 (en) * | 2004-01-28 | 2007-10-04 | Collegium Pharmaceutical, Inc. | Gelled Periodontal Anesthetic Preparation |
| US9492245B2 (en) | 2004-02-27 | 2016-11-15 | Align Technology, Inc. | Method and system for providing dynamic orthodontic assessment and treatment profiles |
| RU2288699C2 (ru) * | 2004-03-23 | 2006-12-10 | Дж. Б. Кемикалс Энд Фармасьютикалс Лимитед | Гелевая композиция для лечения стоматологических заболеваний и способ ее получения |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| US7858115B2 (en) * | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| US20060115785A1 (en) | 2004-11-30 | 2006-06-01 | Chunhua Li | Systems and methods for intra-oral drug delivery |
| US20060115782A1 (en) * | 2004-11-30 | 2006-06-01 | Chunhua Li | Systems and methods for coating a dental appliance |
| US20070059350A1 (en) * | 2004-12-13 | 2007-03-15 | Kennedy John P | Agents for controlling biological fluids and methods of use thereof |
| US20060127437A1 (en) * | 2004-12-13 | 2006-06-15 | Misty Anderson Kennedy | Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids |
| US9649382B2 (en) * | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
| ATE501710T1 (de) * | 2005-01-14 | 2011-04-15 | Camurus Ab | Somatostatin-analog-formulierungen |
| KR101245022B1 (ko) | 2005-01-21 | 2013-03-19 | 카무러스 에이비 | 약제학적 지질 조성물 |
| SE531318C2 (sv) * | 2007-02-22 | 2009-02-24 | Tigran Technologies Ab Publ | Injicerbar suspension innefattande titan-,titanlegerings- eller titanoxidpartiklar av mikrostruktur |
| US7878805B2 (en) | 2007-05-25 | 2011-02-01 | Align Technology, Inc. | Tabbed dental appliance |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| ES2411983T3 (es) * | 2007-09-12 | 2013-07-09 | Galderma Research & Development | Utilización de excipientes como conservantes y composiciones farmacéuticas que los contienen |
| US8738394B2 (en) | 2007-11-08 | 2014-05-27 | Eric E. Kuo | Clinical data file |
| FR2926996B1 (fr) * | 2008-01-31 | 2013-06-21 | Ethypharm Sa | Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine |
| US8108189B2 (en) | 2008-03-25 | 2012-01-31 | Align Technologies, Inc. | Reconstruction of non-visible part of tooth |
| US9492243B2 (en) | 2008-05-23 | 2016-11-15 | Align Technology, Inc. | Dental implant positioning |
| US8092215B2 (en) | 2008-05-23 | 2012-01-10 | Align Technology, Inc. | Smile designer |
| US8172569B2 (en) | 2008-06-12 | 2012-05-08 | Align Technology, Inc. | Dental appliance |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| WO2010033726A2 (en) | 2008-09-17 | 2010-03-25 | The Brigham And Women's Hospital, Inc. | Drug delivery composition comprising a self-assembled gelator |
| US8152518B2 (en) | 2008-10-08 | 2012-04-10 | Align Technology, Inc. | Dental positioning appliance having metallic portion |
| US8292617B2 (en) | 2009-03-19 | 2012-10-23 | Align Technology, Inc. | Dental wire attachment |
| US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| SI2387391T1 (sl) * | 2009-07-24 | 2017-04-26 | Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Postopek za pripravo tekočega sestavka, ki se nanaša na kožo v obliki pene, in sestavka, ki se lahko nanaša topično |
| US8765031B2 (en) | 2009-08-13 | 2014-07-01 | Align Technology, Inc. | Method of forming a dental appliance |
| SG10201500152UA (en) * | 2009-12-22 | 2015-03-30 | Abbvie Inc | Abt-263 capsule |
| WO2011109472A1 (en) * | 2010-03-02 | 2011-09-09 | Imagenetix, Inc. | Compositions comprising myristic acid and uses thereof |
| US9241774B2 (en) | 2010-04-30 | 2016-01-26 | Align Technology, Inc. | Patterned dental positioning appliance |
| US9211166B2 (en) | 2010-04-30 | 2015-12-15 | Align Technology, Inc. | Individualized orthodontic treatment index |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA2830298C (en) | 2011-03-17 | 2016-08-16 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems comprising lecithin and methods of use thereof |
| WO2012144943A1 (en) * | 2011-04-18 | 2012-10-26 | Lipidor Ab | Liquid carrier for oral delivery of a pharmacologically active agent |
| US9403238B2 (en) | 2011-09-21 | 2016-08-02 | Align Technology, Inc. | Laser cutting |
| US9585959B2 (en) * | 2011-12-05 | 2017-03-07 | Camurus Ab | Robust controlled-release formulations |
| EP2793606A1 (en) * | 2011-12-21 | 2014-10-29 | Hill's Pet Nutrition, Inc. | Treatment or reduction of dental conditions with ascorbyl esters |
| US9375300B2 (en) | 2012-02-02 | 2016-06-28 | Align Technology, Inc. | Identifying forces on a tooth |
| US9220580B2 (en) | 2012-03-01 | 2015-12-29 | Align Technology, Inc. | Determining a dental treatment difficulty |
| US9414897B2 (en) | 2012-05-22 | 2016-08-16 | Align Technology, Inc. | Adjustment of tooth position in a virtual dental model |
| ES2834318T3 (es) | 2012-05-25 | 2021-06-17 | Camurus Ab | Formulaciones de agonistas de receptores de la somatostatina |
| NZ704012A (en) | 2012-07-26 | 2017-09-29 | Camurus Ab | Opioid formulations |
| EP3791861A1 (en) | 2012-07-26 | 2021-03-17 | Camurus AB | Opioid formulations |
| US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
| US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
| US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
| US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
| US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
| US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
| US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
| US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
| US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9610141B2 (en) | 2014-09-19 | 2017-04-04 | Align Technology, Inc. | Arch expanding appliance |
| US10449016B2 (en) | 2014-09-19 | 2019-10-22 | Align Technology, Inc. | Arch adjustment appliance |
| US9744001B2 (en) | 2014-11-13 | 2017-08-29 | Align Technology, Inc. | Dental appliance with cavity for an unerupted or erupting tooth |
| US10504386B2 (en) | 2015-01-27 | 2019-12-10 | Align Technology, Inc. | Training method and system for oral-cavity-imaging-and-modeling equipment |
| US9610242B2 (en) | 2015-08-18 | 2017-04-04 | Concept Labs, Inc. | Water-gel emulsion compositions and methods |
| US11554000B2 (en) | 2015-11-12 | 2023-01-17 | Align Technology, Inc. | Dental attachment formation structure |
| US11931222B2 (en) | 2015-11-12 | 2024-03-19 | Align Technology, Inc. | Dental attachment formation structures |
| US11596502B2 (en) | 2015-12-09 | 2023-03-07 | Align Technology, Inc. | Dental attachment placement structure |
| US11103330B2 (en) | 2015-12-09 | 2021-08-31 | Align Technology, Inc. | Dental attachment placement structure |
| US10568840B2 (en) | 2016-05-06 | 2020-02-25 | The Brigham And Women's Hospital, Inc. | Self assembled gels for controlled delivery of encapsulated agents to cartilage |
| WO2017218947A1 (en) | 2016-06-17 | 2017-12-21 | Align Technology, Inc. | Intraoral appliances with sensing |
| EP3471653B1 (en) | 2016-06-17 | 2021-12-22 | Align Technology, Inc. | Orthodontic appliance performance monitor |
| ES2843501T3 (es) | 2016-07-27 | 2021-07-19 | Align Technology Inc | Escáner intraoral con capacidades de diagnóstico dental |
| WO2018085718A2 (en) | 2016-11-04 | 2018-05-11 | Align Technology, Inc. | Methods and apparatuses for dental images |
| US11026831B2 (en) | 2016-12-02 | 2021-06-08 | Align Technology, Inc. | Dental appliance features for speech enhancement |
| WO2018102770A1 (en) | 2016-12-02 | 2018-06-07 | Align Technology, Inc. | Force control, stop mechanism, regulating structure of removable arch adjustment appliance |
| WO2018102811A1 (en) | 2016-12-02 | 2018-06-07 | Align Technology, Inc. | Methods and apparatuses for customizing rapid palatal expanders using digital models |
| EP3824843B1 (en) | 2016-12-02 | 2024-12-25 | Align Technology, Inc. | Series of palatal expanders |
| US10548700B2 (en) | 2016-12-16 | 2020-02-04 | Align Technology, Inc. | Dental appliance etch template |
| WO2018144991A1 (en) | 2017-02-03 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| US10779718B2 (en) | 2017-02-13 | 2020-09-22 | Align Technology, Inc. | Cheek retractor and mobile device holder |
| WO2018183358A1 (en) | 2017-03-27 | 2018-10-04 | Align Technology, Inc. | Apparatuses and methods assisting in dental therapies |
| US10613515B2 (en) | 2017-03-31 | 2020-04-07 | Align Technology, Inc. | Orthodontic appliances including at least partially un-erupted teeth and method of forming them |
| EP3621594A1 (en) | 2017-05-08 | 2020-03-18 | Alivio Therapeutics, Inc. | Formulation of nanostructured gels for increased agent loading and adhesion |
| US11045283B2 (en) | 2017-06-09 | 2021-06-29 | Align Technology, Inc. | Palatal expander with skeletal anchorage devices |
| WO2018232299A1 (en) | 2017-06-16 | 2018-12-20 | Align Technology, Inc. | Automatic detection of tooth type and eruption status |
| US10639134B2 (en) | 2017-06-26 | 2020-05-05 | Align Technology, Inc. | Biosensor performance indicator for intraoral appliances |
| US10885521B2 (en) | 2017-07-17 | 2021-01-05 | Align Technology, Inc. | Method and apparatuses for interactive ordering of dental aligners |
| WO2019018784A1 (en) | 2017-07-21 | 2019-01-24 | Align Technology, Inc. | ANCHOR OF CONTOUR PALATIN |
| CN115462921B (zh) | 2017-07-27 | 2025-05-06 | 阿莱恩技术有限公司 | 牙齿着色、透明度和上釉 |
| WO2019023631A1 (en) | 2017-07-27 | 2019-01-31 | Align Technology, Inc. | SYSTEM AND METHODS FOR TREATING AN ORTHODONTIC ALIGNMENT USING OPTICAL COHERENCE TOMOGRAPHY |
| US12274597B2 (en) * | 2017-08-11 | 2025-04-15 | Align Technology, Inc. | Dental attachment template tray systems |
| WO2019035979A1 (en) | 2017-08-15 | 2019-02-21 | Align Technology, Inc. | EVALUATION AND CALCULATION OF BUCCAL CORRIDOR |
| WO2019036677A1 (en) | 2017-08-17 | 2019-02-21 | Align Technology, Inc. | SURVEILLANCE OF CONFORMITY OF DENTAL DEVICE |
| WO2019071019A1 (en) | 2017-10-04 | 2019-04-11 | Align Technology, Inc. | INTRAORAL APPARATUS FOR SAMPLING MOUTH TISSUE |
| US10813720B2 (en) | 2017-10-05 | 2020-10-27 | Align Technology, Inc. | Interproximal reduction templates |
| CN114939001B (zh) | 2017-10-27 | 2025-02-18 | 阿莱恩技术有限公司 | 替代咬合调整结构 |
| US11576752B2 (en) | 2017-10-31 | 2023-02-14 | Align Technology, Inc. | Dental appliance having selective occlusal loading and controlled intercuspation |
| US11096763B2 (en) | 2017-11-01 | 2021-08-24 | Align Technology, Inc. | Automatic treatment planning |
| US11534974B2 (en) | 2017-11-17 | 2022-12-27 | Align Technology, Inc. | Customized fabrication of orthodontic retainers based on patient anatomy |
| US11219506B2 (en) | 2017-11-30 | 2022-01-11 | Align Technology, Inc. | Sensors for monitoring oral appliances |
| WO2019118876A1 (en) | 2017-12-15 | 2019-06-20 | Align Technology, Inc. | Closed loop adaptive orthodontic treatment methods and apparatuses |
| US10980613B2 (en) | 2017-12-29 | 2021-04-20 | Align Technology, Inc. | Augmented reality enhancements for dental practitioners |
| CN114587237B (zh) | 2018-01-26 | 2025-09-30 | 阿莱恩技术有限公司 | 诊断性口内扫描和追踪 |
| US11937991B2 (en) | 2018-03-27 | 2024-03-26 | Align Technology, Inc. | Dental attachment placement structure |
| CN108498376B (zh) * | 2018-04-02 | 2020-11-13 | 榛硕（武汉）智能科技有限公司 | 一种甲基硅油乳液及其制备方法 |
| KR102736991B1 (ko) | 2018-04-11 | 2024-12-03 | 얼라인 테크널러지, 인크. | 해제 가능한 구개 확장기 |
| CA3113948A1 (en) | 2018-10-11 | 2020-04-16 | Alivio Therapeutics, Inc. | Non-injectable hydrogel formulations for smart release |
| AU2019363244B2 (en) | 2018-10-15 | 2024-10-03 | Cipla Limited | Pharmaceutical formulation |
| EP3848016A1 (en) * | 2020-01-08 | 2021-07-14 | 3M Innovative Properties Company | Oral care composition containing fatty acid components for treating caries |
| US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
| WO2025110709A1 (ko) * | 2023-11-22 | 2025-05-30 | 엠엑스바이오 주식회사 | 치주 질환의 예방 또는 치료용 조성물 및 치과용 복합 항생제 연고 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5230899A (en) * | 1985-08-07 | 1993-07-27 | Smithkline Beecham Corporation | Methods and compositions for making liposomes |
| US5262164A (en) | 1989-11-17 | 1993-11-16 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
| US5230895A (en) * | 1990-05-01 | 1993-07-27 | Copley Pharmaceutical Inc. | Sustained released delivery system for use in the periodontal pocket |
| US5567456A (en) * | 1991-11-04 | 1996-10-22 | Creative Products Inc. Of Rossville | Food release compositions with organic fluidizing agents |
| CA2082561A1 (en) * | 1991-11-12 | 1993-05-13 | Francis J. Leng | Antiperspirant materials and compositions |
| JP3190441B2 (ja) * | 1992-07-20 | 2001-07-23 | エーザイ株式会社 | 塩酸アゼラスチンを含有する安定な製剤 |
| GB9224010D0 (en) | 1992-11-16 | 1993-01-06 | Phares Pharma Holland | Composition and method |
| CA2168260C (en) | 1993-07-28 | 2000-04-11 | Marianna Foldvari | Biphasic multilamellar lipid vesicles |
| ATE223202T1 (de) * | 1994-09-30 | 2002-09-15 | Mika Pharma Ges Fuer Die Entwi | Pharmazeutische zusammensetzung |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
-
1998
- 1998-04-30 BE BE9800329A patent/BE1011899A6/fr active
-
1999
- 1999-04-16 JP JP2000546752A patent/JP2002513748A/ja active Pending
- 1999-04-16 DE DE69901951T patent/DE69901951T2/de not_active Expired - Fee Related
- 1999-04-16 DE DE69927963T patent/DE69927963T2/de not_active Expired - Fee Related
- 1999-04-16 BR BR9910066-5A patent/BR9910066A/pt not_active Application Discontinuation
- 1999-04-16 ES ES99923418T patent/ES2249891T3/es not_active Expired - Lifetime
- 1999-04-16 EP EP99923418A patent/EP1073415B1/fr not_active Expired - Lifetime
- 1999-04-16 TR TR2000/03158T patent/TR200003158T2/xx unknown
- 1999-04-16 NZ NZ507707A patent/NZ507707A/en unknown
- 1999-04-16 ID IDW20002199A patent/ID26221A/id unknown
- 1999-04-16 ES ES99919243T patent/ES2178430T3/es not_active Expired - Lifetime
- 1999-04-16 RS YUP-666/00A patent/RS50025B/sr unknown
- 1999-04-16 KR KR1020007011844A patent/KR100567975B1/ko not_active Expired - Fee Related
- 1999-04-16 CA CA002330500A patent/CA2330500C/fr not_active Expired - Fee Related
- 1999-04-16 IL IL13911399A patent/IL139113A0/xx not_active IP Right Cessation
- 1999-04-16 AU AU37085/99A patent/AU3708599A/en not_active Abandoned
- 1999-04-16 WO PCT/EP1999/002552 patent/WO1999056726A1/fr not_active Ceased
- 1999-04-16 DK DK99923418T patent/DK1073415T3/da active
- 1999-04-16 EP EP99919243A patent/EP1073414B1/fr not_active Expired - Lifetime
- 1999-04-16 AT AT99919243T patent/ATE219659T1/de not_active IP Right Cessation
- 1999-04-16 JP JP2000546753A patent/JP2002513749A/ja not_active Withdrawn
- 1999-04-16 EA EA200001125A patent/EA002530B1/ru not_active IP Right Cessation
- 1999-04-16 HU HU0101580A patent/HU226556B1/hu not_active IP Right Cessation
- 1999-04-16 CN CNB998062669A patent/CN1183901C/zh not_active Expired - Fee Related
- 1999-04-16 AU AU40308/99A patent/AU738455B2/en not_active Ceased
- 1999-04-16 WO PCT/EP1999/002551 patent/WO1999056725A1/fr not_active Ceased
- 1999-04-16 AT AT99923418T patent/ATE307569T1/de not_active IP Right Cessation
- 1999-04-16 US US09/674,159 patent/US6464987B1/en not_active Expired - Fee Related
-
2000
- 2000-04-16 US US09/674,163 patent/US6471970B1/en not_active Expired - Fee Related
- 2000-10-17 BG BG104872A patent/BG64723B1/bg unknown
- 2000-10-17 IS IS5669A patent/IS2354B/is unknown
- 2000-10-23 ZA ZA200005915A patent/ZA200005915B/xx unknown
- 2000-10-27 NO NO20005431A patent/NO20005431L/no not_active Application Discontinuation
-
2002
- 2002-09-17 US US10/259,366 patent/US6818224B2/en not_active Expired - Fee Related
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007510705A (ja) * | 2003-11-07 | 2007-04-26 | カムルス エービー | 脂質及びカチオン性ペプチドの組成物 |
| JP2008501676A (ja) * | 2004-06-04 | 2008-01-24 | カムルス エービー | 流体デポ製剤 |
| JP2008518916A (ja) * | 2004-10-28 | 2008-06-05 | アイデックス ラボラトリーズ，インコーポレイティド | 医薬活性化合物を制御して搬送するための組成物 |
| JP2008526932A (ja) * | 2005-01-14 | 2008-07-24 | カムルス エービー | 局所用生体付着性製剤 |
| JP2008526933A (ja) * | 2005-01-14 | 2008-07-24 | カムルス エービー | ソマトスタチン類似体製剤 |
| JP2008526934A (ja) * | 2005-01-14 | 2008-07-24 | カムルス エービー | ＧｎＲＨ類似体製剤 |
| JP2012214494A (ja) * | 2005-01-14 | 2012-11-08 | Camurus Ab | 局所用生体付着性製剤 |
| JP2008542437A (ja) * | 2005-06-06 | 2008-11-27 | カムルス エービー | Ｇｌｐ−１類似体製剤 |
| US11672864B2 (en) | 2010-09-24 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
| JP2014527896A (ja) * | 2011-09-28 | 2014-10-23 | グローバス メディカル インコーポレイティッド | 生分解性パテ組成物およびインプラントデバイス、方法、ならびにこれらに関するキット |
| JP2015516411A (ja) * | 2012-05-10 | 2015-06-11 | ペインレフォーム リミテッド | 疎水性有効成分のデポー製剤及びその調製方法 |
| US9668974B2 (en) | 2012-05-10 | 2017-06-06 | Painreform Ltd. | Depot formulations of a local anesthetic and methods for preparation thereof |
| JP2017222729A (ja) * | 2012-05-10 | 2017-12-21 | ペインリフォーム リミテッド | 局所麻酔薬のデポー製剤及びその調製方法 |
| US9849088B2 (en) | 2012-05-10 | 2017-12-26 | Painreform Ltd. | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
| JP2018035179A (ja) * | 2012-05-10 | 2018-03-08 | ペインレフォーム リミテッド | 疎水性有効成分のデポー製剤及びその調製方法 |
| US10206876B2 (en) | 2012-05-10 | 2019-02-19 | Painreform Ltd. | Depot formulations of a local anesthetic and methods for preparation thereof |
| JP2015516412A (ja) * | 2012-05-10 | 2015-06-11 | ペインリフォーム リミテッド | 局所麻酔薬のデポー製剤及びその調製方法 |
| JP2018530561A (ja) * | 2015-10-08 | 2018-10-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 被包した薬剤の送達のための安定化させた集合ナノ構造体 |
| JP2022103380A (ja) * | 2015-10-08 | 2022-07-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 被包した薬剤の送達のための安定化させた集合ナノ構造体 |
| JP7121654B2 (ja) | 2015-10-08 | 2022-08-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 被包した薬剤の送達のための安定化させた集合ナノ構造体 |
| JP7092922B1 (ja) | 2021-06-11 | 2022-06-28 | キユーピー株式会社 | 製剤 |
| WO2022260169A1 (ja) * | 2021-06-11 | 2022-12-15 | キユーピー株式会社 | 製剤 |
| JP2022189470A (ja) * | 2021-06-11 | 2022-12-22 | キユーピー株式会社 | 製剤 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU738455B2 (en) | Gellable pharmaceutical compositions | |
| JP6577548B2 (ja) | 疎水性有効成分のデポー製剤及びその調製方法 | |
| US20130190341A1 (en) | High bioavailability opioid formulations | |
| HUP0301921A2 (hu) | Elnyújtott hatóanyag-leadású készítmények hidrofil vegyületek parenterális adagolására | |
| JP2001516714A (ja) | 持続放出性リポソーム麻酔組成物 | |
| JP2005531595A (ja) | ホスファチジルコリンを使用する局所的医薬伝達 | |
| CN109010255B (zh) | 阿片样物质制剂 | |
| TW202228645A (zh) | 緩釋製劑組合物 | |
| CA2169172A1 (en) | Percutaneously absorbable preparation | |
| KR102628523B1 (ko) | GnRH 유도체를 포함하는 주사용 조성물 | |
| CN1213964A (zh) | 抗糖皮质激素药物 | |
| CN109091451B (zh) | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 | |
| CZ20004010A3 (cs) | Farmaceutické kompozice schopné vytvářet gel | |
| MXPA00010497A (en) | Pharmaceutical compositions capable of being gelled | |
| HK1033263B (en) | Pharmaceutical compositions capable of being gelled | |
| HK1083009B (en) | Topical drug delivery using phosphatidylcholine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080610 |